RxDoctor Payments Data

Cindy Altonburg, APRN

Family · Austin, TXNPI 1124722582

Payments from drug & device makers

$6,096in general payments, 2019–2025

Across 190 payments — averaging $32.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • AbbVie$729
  • Sumitomo Pharma America, Inc.$406
  • Johnson & Johnson$381
  • Endo USA, Inc.$257
  • Bayer$152
  • plus $952 from 15 others

What the payments were for

  • Travel & lodging$3566%
  • Food & beverage$5,67393%
  • Education$671%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,096 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$183,402
Medicare patients
445
Services billed
7,189

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron144$112,201
MyrbetriqMirabegron130$71,848
Mirabegron ErMirabegron37$21,583
Estradiol202$12,980
Fosfomycin Tromethamine33$4,423
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst294$3,941
Solifenacin Succinate92$2,352
Methenamine Hippurate41$1,830
Fesoterodine Fumarate ErFesoterodine Fumarate19$929
Tamsulosin Hcl99$915
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav87$683
Potassium Citrate ErPotassium Citrate12$629
Oxybutynin Chloride ErOxybutynin Chloride40$495
Cephalexin36$394
Fluconazole33$270

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$406$112,201144 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.

Other family in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →